Time-Restricted Eating as a Dietary Intervention for Polyendocrine Metabolic Ovarian Syndrome (PMOS): Protocol for a Randomized Controlled Trial
- 1Department of Human Nutrition and Dietetics, Poznań University of Life Sciences, Wojska Polskiego 31, 60-624 Poznan, Poland
- 2Department of Bromatology, Poznań University of Medical Sciences, Rokietnicka 3, 60-806 Poznan, Poland
- 3Department of Animal Physiology and Biochemistry, Poznań University of Life Sciences, Wołyńska 35, 60-637 Poznan, Poland
Abstract
Background: Time-restricted eating (TRE) appears to be a promising dietary strategy for women with polyendocrine metabolic ovarian syndrome (PMOS), with potential benefits for insulin resistance and metabolic health. Emerging evidence also suggests that TRE may be associated with changes in gut microbiota composition and microbial metabolites, as well as circulating biomarkers involved in metabolic regulation. However, the relationships among these factors remain poorly understood. Objective: The aim of this study is to test the hypothesis that adding TRE to Healthy Eating Plate recommendations is more effective in improving insulin resistance, assessed using HOMA-IR, than Healthy Eating Plate recommendations alone in women with PMOS. Exploratory analyses will investigate changes in gut microbiota composition, microbial metabolites, and circulating concentrations of neuroactive compounds. Methods: This two-arm, parallel-group randomized controlled trial will compare 8-h TRE with unrestricted meal timing in women aged 18 to 40 years with PMOS and a BMI of 25–40 kg/m2 with a 1:1 allocation ratio. Both groups will receive Healthy Eating Plate-based dietary advice and attend four visits; the TRE protocol will be followed for 8 weeks. The primary outcome will be a change in HOMA-IR from baseline to week 8. We will also assess changes in glucose and lipid metabolism, circulating neuroactive compounds, including GABA and kisspeptin, anthropometric parameters, hormonal profile, composition and diversity of the microbiota and its metabolites. Discussion: We anticipate that this study will expand the limited evidence regarding TRE in women with PMOS and provide exploratory insights into the relationships among gut microbiota composition, microbial metabolites, circulating GABA and kisspeptin, and insulin resistance. The findings may help identify potential mechanisms underlying the metabolic effects of TRE in this population. Protocol version: 1.1, August 2026. Trial registration number: NCT06204965. Trial status: Participant recruitment has not yet commenced.
Related
- 12-week yoga intervention effect on metabolome in Polyendocrine Metabolic Ovarian Syndrome (PMOS): An LC-MS-based study.
- Semen Quality and Metabolic Biomarker Changes Following a 12-Week Combined Exercise Program in Healthy Adult Men: A Non-Randomized Controlled Intervention Study
- Effects of time-restricted eating and supervised exercise on intrahepatic fat and cardiometabolic health in adults with obesity: the TEMPUS randomized controlled trial
- Efficacy of a weighted-vest aerobic dance intervention for enhancing lower extremity strength and mobility in older adults: a randomized controlled trial
- Culturally adapted home-based intervention to improve child’s development in Arab toddlers in Israel: study protocol for a randomized controlled trial
BibTeX
@article{pieczynskazajac2026timerestricted,
title = {{Time-Restricted Eating as a Dietary Intervention for Polyendocrine Metabolic Ovarian Syndrome (PMOS): Protocol for a Randomized Controlled Trial}},
author = {Joanna Maria Pieczyńska-Zając and Sławomira Drzymała-Czyż and Ewa Pruszyńska-Oszmałek and Paweł Antoni Kołodziejski and Joanna Bajerska},
journal = {Nutrients},
year = {2026},
month = oct,
doi = {10.3390/nu18213559},
url = {https://www.mdpi.com/2072-6643/18/21/3559},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Time-Restricted Eating as a Dietary Intervention for Polyendocrine Metabolic Ovarian Syndrome (PMOS): Protocol for a Randomized Controlled Trial
AU - Joanna Maria Pieczyńska-Zając
AU - Sławomira Drzymała-Czyż
AU - Ewa Pruszyńska-Oszmałek
AU - Paweł Antoni Kołodziejski
AU - Joanna Bajerska
PY - 2026
DA - 2026/10/28
JO - Nutrients
DO - 10.3390/nu18213559
UR - https://www.mdpi.com/2072-6643/18/21/3559
AB - Background: Time-restricted eating (TRE) appears to be a promising dietary strategy for women with polyendocrine metabolic ovarian syndrome (PMOS), with potential benefits for insulin resistance and metabolic health. Emerging evidence also suggests that TRE may be associated with changes in gut microbiota composition and microbial metabolites, as well as circulating biomarkers involved in metabolic regulation. However, the relationships among these factors remain poorly understood. Objective: The aim of this study is to test the hypothesis that adding TRE to Healthy Eating Plate recommendations is more effective in improving insulin resistance, assessed using HOMA-IR, than Healthy Eating Plate recommendations alone in women with PMOS. Exploratory analyses will investigate changes in gut microbiota composition, microbial metabolites, and circulating concentrations of neuroactive compounds. Methods: This two-arm, parallel-group randomized controlled trial will compare 8-h TRE with unrestricted meal timing in women aged 18 to 40 years with PMOS and a BMI of 25–40 kg/m2 with a 1:1 allocation ratio. Both groups will receive Healthy Eating Plate-based dietary advice and attend four visits; the TRE protocol will be followed for 8 weeks. The primary outcome will be a change in HOMA-IR from baseline to week 8. We will also assess changes in glucose and lipid metabolism, circulating neuroactive compounds, including GABA and kisspeptin, anthropometric parameters, hormonal profile, composition and diversity of the microbiota and its metabolites. Discussion: We anticipate that this study will expand the limited evidence regarding TRE in women with PMOS and provide exploratory insights into the relationships among gut microbiota composition, microbial metabolites, circulating GABA and kisspeptin, and insulin resistance. The findings may help identify potential mechanisms underlying the metabolic effects of TRE in this population. Protocol version: 1.1, August 2026. Trial registration number: NCT06204965. Trial status: Participant recruitment has not yet commenced.
SN - 2072-6643
ER -